NativeMed Review
Best for: buyers comfortable with sub-$200 promotional compounded GLP-1 pricing who can verify pharmacy partner identity directly with NativeMed support before subscribing
NativeMed, LLC (nativemed.net) is a Miami, FL-based cash-pay telehealth provider offering compounded semaglutide at promotional $149/mo (regular $299) and compounded tirzepatide at promotional $183/mo (regular $399), plus NAD+ and several non-weight-loss generics. LegitScript certified.
Medium confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
NativeMed is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (sale) | compounded | $149 |
| Compounded tirzepatide (sale) | compounded | $183 |
✓ Pros
- •LegitScript certified per the homepage footer (independently verifiable)
- •Promotional pricing publicly displayed: $149/mo semaglutide, $183/mo tirzepatide (sale from $299/$399 regular)
- •Async questionnaire workflow with synchronous visit triggered when state law requires it
✗ Cons
- •Pharmacy partners are NOT publicly named — material gap for YMYL disclosure (described only as 'USA-based pharmacies' / 'accredited pharmacies')
- •States served list is not publicly enumerated
- •Pricing displayed as promotional sale price — readers should confirm whether the $149/$183 holds beyond the first month or escalates to the $299/$399 'regular' price
- •Trustpilot reviews displayed on homepage — we do NOT cite Trustpilot as a primary source per editorial policy
Ready to start with NativeMed?
Starting at $149/month. See current pricing and start your free consultation.
Sources & methodology
Our NativeMed review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to NativeMed
Editorial score · methodology
Editorial score · methodology
Alloy
Best for: women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory
Editorial score · methodology
Frequently Asked Questions
Ready to start with NativeMed?
Starting at $149/month. See current pricing and start your free consultation.